

# Call for Abstracts

## The 12th Annual Congress of Asian Society of Veterinary Surgery (AiSVS)

The program committee of the 12th Annual Congress of AiSVS is calling for contributions for Original Research and Clinical Case to be presented on December 20-21, 2024 in Sapporo, Japan.

**Original Research Session:** This session will consist of oral presentations (15 minutes including 5 min discussion) or poster presentations of original scientific studies (basic, applied, clinical) in animals.

**Clinical Case Session:** This session will consist of oral presentations (10 minutes including 3 min discussion) or poster presentations of interesting case reports.

Posters will be put up on Friday afternoon, December 20, with a discussion time around noon on Saturday, December 21.

The program committee of the 12th Annual Congress of AiSVS may request you to modify your presentation time. Thank you for your cooperation and understanding.

All presentations must be delivered in English. Studies submitted should not have been presented at a national or international meeting prior to the 12th Annual Congress of AiSVS. Abstracts submitted for all sessions should adhere strictly to the format guidelines for the 12th Annual Congress of AiSVS. Each abstract will be evaluated by members of the program committees and scored based on design, originality, and relevance to each subject. The abstracts will be ranked according to score and selected for presentation in the session requested, based on available space. All oral presentations are required to be prepared for utilizing Power Point for LCD projection. The size of poster presentation will be informed to authors when they receive the acceptance of their abstract as poster presentation.

The deadline for reception of all abstracts is **October 7, 2024**. Abstracts must be submitted to the program committee of 12th Annual Congress of AiSVS by **uploading via website**. The desired presentation type, names of presenters, their affiliations and titles, and abstracts should all be prepared in English and submitted using the online submission form provided on the website.

**For inquiries regarding this matter, please contact:** s-takagi@azabu-u.ac.jp

# Format for Abstracts

Submission Deadline: **October 7, 2024**

A. Page Format: margins: 1 inch (2.5 cm) top, bottom, left and right, single spaced; laser printer quality  
- **1 page maximum (including title, authors, affiliation, abstract body, sponsorship, table)**

B. Style:

1. Title: **Bold**, Times New Roman, 12 pts, centered, **no capital letters** except proper names or product name
  - Leave a blank line between the title and authors.
2. Authors:
  - Include all authors.
  - Format: initials followed by last name only, no degrees.
  - Times New Roman, 12 points, **not bold**, centered.
  - Affiliation numbered in superscript following last name (leave a blank line between author and affiliation).
3. Affiliation:
  - List affiliation of all authors in order following superscript.
  - Name of department, School/Institution, City, State, Country (do not include address).
  - Times New Roman, 12 points, **not bold**, centered.
  - Leave a blank line between affiliation and the abstract body.
4. Body: For original studies, the body of the abstract should contain the study objective, a brief statement of methods, statement of results, and conclusions. For Case Reports, the body should contain background, objectives, relative data, case summary, and conclusions. Results stated in the abstracts must be complete (though concise) and final. It is not *acceptable to state "results will be discussed."* Results presented in oral or poster format must match those presented in the abstract.
  - A. Times New Roman, 12 point, single spaced, right margin **not justified**, begin with the word **"Abstract:"** in bold, followed by the text.
  - B. Spell out any abbreviation in full on the first mention, followed by the abbreviation in parentheses.
  - C. Statistics: Describe statistical method and computer program used and if space permits, discuss eligibility of experimental subjects, give details about randomization and blinding, identify numbers of observations, treatment complications, and losses to observation (e.g. dropouts).
  - D. Products listed, include the manufacturer's name and address. Example: modified cyclosporine (Atopica: Novartis Animal Health, Greensboro, NC)
  - E. Breed names are adjectives not nouns (ie: Siamese cat, not "Siamese"), and should only be capitalized if proper name (ie: German shepherd dog, not German Shepherd Dog).
  - F. Numbers up to and including 10 are spelled out unless associated with time (days, weeks, months). Use "h" for hours, "min" for minutes, and "sec" for seconds.
  - G. Data may be summarized to conserve text such as "3/9 dogs".
  - H. Drug doses are reported as mg kg<sup>-1</sup> not as mg/kg and lab data should be reported in IU units.
5. Sponsorship: Identify corporate sponsorship of the study or drugs supplied, separated from the body of the abstract by one line space.
6. Table: only one small table is permitted, provided that it does not contain more than 5 rows and columns.
7. When finished with your abstract, count the words to ensure you have not exceeded the prescribed limit. All abstracts may not exceed 250 words (EXCLUDING title, author list, affiliations, and sponsorship statement). **Abstracts exceeding these limits will be returned to the author unreviewed.**
8. References are not to be included in the abstract

**The effect of transcatheter arterial embolization in clinically healthy dogs**

Y. Oishi<sup>1</sup>, K. Tani<sup>1</sup>, K. Ozono<sup>1</sup>, H. Nakazawa<sup>1</sup>, K. Itamoto<sup>2</sup>, T. Haraguchi<sup>2</sup>, Y. Taura<sup>1</sup>,

<sup>1</sup>Department of Veterinary Surgery and <sup>2</sup>Animal Medical Center, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.

**Abstract:** Transcatheter Arterial Embolization (TAE) is widely used as an effective treatment for hepatic tumor in human. However, little information is available in veterinary field. In this study, we investigated the effect of TAE in clinically healthy dogs. Six beagle dogs without clinical signs relating to liver disease were entered into the study. In all dogs, microcatheter could be inserted successfully in the left hepatic artery through the femoral artery and the celiac artery under anesthesia. The porous gelatin particles with contrast medium were injected through the catheter. The left hepatic artery was selectively embolized in all dogs. CT scanning revealed that embolized arteries were recanalized at 2 wks after the treatment. Hepatic enzymes increased temporarily (1-2 wks) and decreased subsequently in 3-4 wks, then within normal range in 8wks after the treatment. Only one dog showed elevated lipase. However, any clinical abnormalities were not observed in all dogs during the examination. Histological differences were not observed between arteries with or without the treatment. Taken together, these results suggested that TAE is comparatively safe to liver tissue in clinically healthy dogs.

This study was supported by Grants-in-Aid for Scientific Research (xx4504xx).